CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
2013

CDDO-Me: A New Treatment for Pancreatic Cancer

publication 10 minutes Evidence: moderate

Author Information

Author(s): Deeb Dorrah, Gao Xiaohua, Arbab Ali S., Barton Kenneth, Dulchavsky Scott A., Gautam Subhash C.

Primary Institution: Henry Ford Health System

Hypothesis

Can CDDO-Me effectively inhibit the growth of pancreatic cancer cells and induce apoptosis?

Conclusion

CDDO-Me significantly inhibits the growth of pancreatic cancer cells by inducing apoptosis through multiple pathways.

Supporting Evidence

  • CDDO-Me inhibited the growth of pancreatic cancer cells at low concentrations.
  • Treatment with CDDO-Me led to increased apoptosis as indicated by annexin V-FITC binding.
  • CDDO-Me induced mitochondrial depolarization and release of cytochrome C.
  • CDDO-Me inhibited key survival signaling proteins like Akt and mTOR.

Takeaway

CDDO-Me is a new medicine that helps kill pancreatic cancer cells by making them die in a special way called apoptosis.

Methodology

The study evaluated the effects of CDDO-Me on pancreatic cancer cell lines using various assays to measure cell growth and apoptosis.

Limitations

The study primarily focused on in vitro results, and further validation in vivo is needed.

Digital Object Identifier (DOI)

10.3390/cancers2041779

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication